Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.
about
Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse modelSm10.3, a member of the micro-exon gene 4 (MEG-4) family, induces erythrocyte agglutination in vitro and partially protects vaccinated mice against Schistosoma mansoni infectionAn interspecific Nicotiana hybrid as a useful and cost-effective platform for production of animal vaccinesThe avian influenza vaccine Emerflu. Why did it fail?Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial.Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant.Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinationsSafety and Immunogenicity of a Single Low Dose or High Dose of Clade 2 Influenza A(H5N1) Inactivated Vaccine in Adults Previously Primed With Clade 1 Influenza A(H5N1) Vaccine.Preparation, characterization, and immunogenicity in mice of a recombinant influenza H5 hemagglutinin vaccine against the avian H5N1 A/Vietnam/1203/2004 influenza virusPersistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 AdjuvantInfluenza immunology evaluation and correlates of protection: a focus on vaccines.Specific recognition of influenza A/H1N1/2009 antibodies in human serum: a simple virus-free ELISA method.Coated protein nanoclusters from influenza H7N9 HA are highly immunogenic and induce robust protective immunity.Cell-Based Systems Biology Analysis of Human AS03-Adjuvanted H5N1 Avian Influenza Vaccine Responses: A Phase I Randomized Controlled TrialEvaluation of multivalent H2 influenza pandemic vaccines in mice.Individual antibody and T cell responses to vaccination and infection with the 2009 pandemic swine-origin H1N1 influenza virus.Humoral and cell-mediated immune responses to monovalent 2009 influenza A/H1N1 and seasonal trivalent influenza vaccines in high-risk childrenH5N1 virus-like particle vaccine elicits cross-reactive neutralizing antibodies that preferentially bind to the oligomeric form of influenza virus hemagglutinin in humans.Safety and immune responses in children after concurrent or sequential 2009 H1N1 and 2009-2010 seasonal trivalent influenza vaccinationsA plant-produced H1N1 trimeric hemagglutinin protects mice from a lethal influenza virus challenge.An overview of the highly pathogenic H5N1 influenza virus.Discovery of novel benzoquinazolinones and thiazoloimidazoles, inhibitors of influenza H5N1 and H1N1 viruses, from a cell-based high-throughput screen.Impact of antigenic and genetic drift on the serologic surveillance of H5N2 avian influenza viruses.Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variantSerologic assays for influenza surveillance, diagnosis and vaccine evaluation.Comparison of serological assays for detecting antibodies in ducks exposed to H5 subtype avian influenza virusLethal coinfection of influenza virus and Streptococcus pneumoniae lowers antibody response to influenza virus in lung and reduces numbers of germinal center B cells, T follicular helper cells, and plasma cells in mediastinal lymph Node.Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women.Overview of Serological Techniques for Influenza Vaccine Evaluation: Past, Present and Future.Direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes.Standardization of Hemagglutination Inhibition Assay for Influenza Serology Allows for High Reproducibility between Laboratories.Immunological assessment of influenza vaccines and immune correlates of protection.An influenza A virus agglutination test using antibody-like polymers.Preexisting Immunity, Not Frailty Phenotype, Predicts Influenza Postvaccination Titers among Older Veterans.Sterilizing immunity to influenza virus infection requires local antigen-specific T cell response in the lungsNative Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses.Impact of erythrocyte species on assays for influenza serology.
P2860
Q27330580-DE82A6BD-39F9-4B69-B316-09C41C2BC88EQ28541196-AEB4257D-F60B-4FA5-9E78-97909ABDC951Q28730453-6E20BF29-031F-40F3-AD22-E62E0C544376Q30203302-73DD3E78-D2BB-4BA3-AB53-FE7BE4FD5988Q30204573-2F0DDDC2-1287-43E9-A749-7353E437C33EQ30204578-56E73D97-E172-4C54-9D71-368C131BB096Q30369098-3E62F2B5-88F2-40A2-9016-5D8F5D484111Q30372087-CF83CF57-2AC6-41AC-A4EB-A47C2A682301Q30379914-C954B318-17F7-4770-8947-34849EA275BAQ30381280-A03A4F16-4743-499C-8D48-963FD29496A4Q30385397-39F96CA2-F26C-42DF-AA95-6631E94C0894Q30388531-6726E24F-CD2A-42A1-A2B1-A88C9E298A56Q30392895-10EF1D58-07DA-4029-B171-8F341AF0BA39Q30397652-CAC593B0-F274-4224-9DD0-80230F58BDE1Q30398507-5435D989-ACD4-4830-B71C-023363F2465AQ30404512-BC270BDA-A1E0-4C9A-B88E-5E4D18677FA0Q30405955-78EE1718-1DE0-4BEF-B207-4EE291C5F9AFQ30406365-3922D031-7169-457D-A193-177CEBEFF8A2Q30419240-DF25E108-805A-40B0-82D9-AC3602FF3CCDQ30425590-833843A6-649A-4DD4-9155-BF5B7C1FD2C2Q30426011-BFE7AB22-7B2E-45EC-9549-2F9A2E673AEEQ33741316-418D0DC9-A7FC-44DF-84F4-486D11C0222EQ33776223-881D3D2C-BC76-4869-AA32-6EA9534911E0Q33808135-9643B879-BA94-4AC4-9747-F9F3665292DDQ34194336-3645E6BD-35FC-416D-B9C9-8C476E240FE5Q34348163-C0765901-0B5D-4679-A0DB-CDEC113EA4EFQ35115579-B3789F8E-2698-4CED-9E8E-B4ED81134A1AQ35167137-B88C10D7-9734-4D22-9F35-92BF07DD2F15Q35826733-5D9DC606-1F6A-45EB-B797-1BCCBEA2EB0DQ36410040-0567920B-D432-481A-A682-324A5E07949FQ36665657-25D34B11-8791-4F68-AC13-F180C7BB65E3Q38105339-E641B8D8-C330-4D02-8BB9-7DBAE3C90C49Q40177269-D6032041-A2C0-439A-B698-5F16C96151AEQ40374569-C6E2DB27-3864-4518-9FF1-AAA0E1267F83Q40551533-BDB90816-A984-41CE-934D-7F6D6DABACA1Q52673291-7B3F673A-5A71-4EA6-AD9C-A3E18F85A08EQ55239857-1EEAAD06-75A5-4C07-9B1F-02047129C783
P2860
Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure.
description
2009 nî lūn-bûn
@nan
2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Qualification of the hemagglut ...... c influenza vaccine licensure.
@ast
Qualification of the hemagglut ...... c influenza vaccine licensure.
@en
type
label
Qualification of the hemagglut ...... c influenza vaccine licensure.
@ast
Qualification of the hemagglut ...... c influenza vaccine licensure.
@en
prefLabel
Qualification of the hemagglut ...... c influenza vaccine licensure.
@ast
Qualification of the hemagglut ...... c influenza vaccine licensure.
@en
P2093
P2860
P356
P1476
Qualification of the hemagglut ...... c influenza vaccine licensure.
@en
P2093
David Hines
Diana L Noah
E Lucile White
Heather Hill
Mark C Wolff
P2860
P304
P356
10.1128/CVI.00368-08
P577
2009-02-18T00:00:00Z